A share price of Terns Pharmaceuticals Inc [TERN] is currently trading at $4.66, up 3.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The TERN shares have gain 11.48% over the last week, with a monthly amount drifted -18.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on October 31, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $82. Previously, Mizuho started tracking the stock with Buy rating on June 22, 2023, and set its price target to $16. On June 07, 2023, Jefferies initiated with a Buy rating and assigned a price target of $18 on the stock. ROTH MKM started tracking the stock assigning a Buy rating and suggested a price target of $23 on May 31, 2023. BMO Capital Markets initiated its recommendation with a Outperform and recommended $18 as its price target on May 08, 2023. JMP Securities started tracking with a Mkt Outperform rating for this stock on February 14, 2023, and assigned it a price target of $17. In a note dated February 07, 2023, UBS initiated an Buy rating and provided a target price of $19 on this stock.
Terns Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $4.16 and $11.40. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $4.66 at the most recent close of the market. An investor can expect a potential return of 300.64% based on the average TERN price forecast.
Analyzing the TERN fundamentals
Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -75.63%, Pretax Profit Margin comes in at -66.42%, and Net Profit Margin reading is -66.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.51 points at the first support level, and at 4.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.74, and for the 2nd resistance point, it is at 4.81.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Terns Pharmaceuticals Inc [NASDAQ:TERN] is 32.99. On the other hand, the Quick Ratio is 32.99, and the Cash Ratio is 23.67.
Transactions by insiders
Recent insider trading involved Jung Melita Sun, Chief Business Officer, that happened on Nov 30 ’24 when 2250.0 shares were purchased. Chief Executive Officer, Burroughs Amy L. completed a deal on Nov 30 ’24 to buy 510.0 shares. Meanwhile, Chief Medical Officer Kuriakose Emil sold 4481.0 shares on Jan 02 ’25.
